SG11202104362SA - Plasmid constructs for treating cancer and methods of use - Google Patents

Plasmid constructs for treating cancer and methods of use

Info

Publication number
SG11202104362SA
SG11202104362SA SG11202104362SA SG11202104362SA SG11202104362SA SG 11202104362S A SG11202104362S A SG 11202104362SA SG 11202104362S A SG11202104362S A SG 11202104362SA SG 11202104362S A SG11202104362S A SG 11202104362SA SG 11202104362S A SG11202104362S A SG 11202104362SA
Authority
SG
Singapore
Prior art keywords
methods
treating cancer
plasmid constructs
plasmid
constructs
Prior art date
Application number
SG11202104362SA
Inventor
Christopher Twitty
Anandaroop Mukhopadhyay
David A Canton
Mia Han
Erica Browning
Original Assignee
Oncosec Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Inc filed Critical Oncosec Medical Inc
Publication of SG11202104362SA publication Critical patent/SG11202104362SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202104362SA 2018-11-27 2019-11-27 Plasmid constructs for treating cancer and methods of use SG11202104362SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771928P 2018-11-27 2018-11-27
US201962826439P 2019-03-29 2019-03-29
PCT/US2019/063590 WO2020112987A1 (en) 2018-11-27 2019-11-27 Plasmid constructs for treating cancer and methods of use

Publications (1)

Publication Number Publication Date
SG11202104362SA true SG11202104362SA (en) 2021-06-29

Family

ID=70854110

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104362SA SG11202104362SA (en) 2018-11-27 2019-11-27 Plasmid constructs for treating cancer and methods of use

Country Status (12)

Country Link
US (1) US20220041724A1 (en)
EP (1) EP3887528A4 (en)
JP (1) JP7514231B2 (en)
KR (1) KR20210084648A (en)
CN (1) CN113412334A (en)
AU (1) AU2019386131A1 (en)
BR (1) BR112021008179A2 (en)
CA (1) CA3120564A1 (en)
IL (1) IL282776A (en)
SG (1) SG11202104362SA (en)
TW (1) TW202039537A (en)
WO (1) WO2020112987A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006922A (en) * 2018-12-11 2021-09-30 Oncosec Medical Inc Multigene construct for immune-modulatory protein expression and methods of use.
JP7137696B2 (en) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド Methods and compositions for preventing type 1 diabetes
AU2020351204A1 (en) 2019-09-18 2022-04-21 Aldevron, Llc Synthetic DNA vectors and methods of use
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US11873507B2 (en) * 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
CN114605543B (en) * 2021-12-17 2023-11-07 台州恩泽医疗中心(集团) Monoclonal antibody of HLA-G isomer molecule HLA-G5 and HLA-G6 and application thereof
CN114316062B (en) * 2022-03-02 2022-06-07 珠海臻谱基因科技有限公司北京分公司 Multispecific antibody targeting HIV gp120 protein and human CD3 molecule and application thereof
WO2024099990A1 (en) * 2022-11-07 2024-05-16 Leibniz-Institut Für Immuntherapie (Lit) TGF-ß SWITCH RECEPTOR CAR T CELLS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340972B (en) * 2008-10-08 2016-08-02 Intrexon Corp Engineered cells expressing multiple immunomodulators and uses thereof.
MX362513B (en) * 2010-03-23 2019-01-22 Intrexon Corp Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof.
CN107847601A (en) * 2015-06-04 2018-03-27 南加利福尼亚大学 The CAR cellular immunotherapies that LYM 1 and LYM 2 is targetted
CA3009123A1 (en) * 2015-12-18 2017-06-22 Oncosec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
CA3034873A1 (en) * 2016-08-26 2018-03-01 Baylor College Of Medicine Constitutively active cytokine receptors for cell therapy

Also Published As

Publication number Publication date
IL282776A (en) 2021-06-30
JP2022512942A (en) 2022-02-07
EP3887528A4 (en) 2022-12-28
CN113412334A (en) 2021-09-17
WO2020112987A1 (en) 2020-06-04
EP3887528A1 (en) 2021-10-06
CA3120564A1 (en) 2020-06-04
BR112021008179A2 (en) 2021-11-03
JP7514231B2 (en) 2024-07-10
KR20210084648A (en) 2021-07-07
AU2019386131A1 (en) 2021-07-01
US20220041724A1 (en) 2022-02-10
TW202039537A (en) 2020-11-01

Similar Documents

Publication Publication Date Title
IL282776A (en) Plasmid constructs for treating cancer and methods of use
ZA202006905B (en) Gene therapy constructs and methods of use
IL284324A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284326A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL289663A (en) Claudin18 antibodies and methods of treating cancer
IL268814A (en) Compositions and methods for treatment of cancer
IL313238A (en) Claudin6 antibodies and methods of treating cancer
IL254842B (en) Therapeutic compositions and methods of use for treating cancer
IL286297A (en) Methods of treating minimal residual cancer
IL268912A (en) Gene therapy constructs and methods for treatment of hearing loss
SG11202010793UA (en) Methods of treating cancer
IL279591A (en) Methods of treating cancer using combination therapy
IL280830A (en) Conjugates for use in methods of treating cancer
IL276203A (en) Compositions and methods of treating cancer
IL304245A (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
SG11202107017TA (en) Methods of treating cancer
SG11202106295WA (en) Compositions and methods for cancer therapy
IL281600A (en) Methods of treating cancer
IL277981A (en) Methods of treating cancer
EP3585819A4 (en) Antibody constructs and methods of treating cancer
IL283912A (en) Methods of treating cancer using platanoside and isomers thereof
GB201820975D0 (en) Methods of cancer treatment
GB201820098D0 (en) Methods of cancer treatment